A large variety of therapeutic classes are currently available for Type 2 diabetes. Even though the current drugs are effective, the treatment remains symptomatic and does not halt the underlying β-cell degeneration. Patients therefore need to take increasing doses or add-on therapies. In addition, other organs (e.g. liver and kidney) suffer from the high blood glucose levels.
reMYND is currently developing a ReS39 drug that not only stops the β-cell degeneration but actually doubles the production of insulin in the pancreas after only 4 weeks of treatment in mice. This beneficial effect of increased endogenous insulin is durably sustained for some time after halting the treatment (= wash-out), as the mice manage glucose much better.
Re-functionalization of degenerated β-cells in the pancreas
Relatively short time until treatment effect
Treatment effect is durably sustained for some time after treatment stop
Clinical trials are currently being prepared to assess this effect in humans as well
End-organ protection will be assessed as well